Overview

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

Status:
Completed

Trial end date:
2018-08-13

Target enrollment:

Participant gender:

Summary

This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.

Phase:

Phase 2

Details

Lead Sponsor:

TG Therapeutics, Inc.